These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 20949636)

  • 21. Extension of adaptive alpha allocation methods for strong control of the family-wise error rate.
    Li H; Sankoh AJ; D'Agostino RB
    Stat Med; 2013 Jan; 32(2):181-95. PubMed ID: 22806685
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How to deal with multiple endpoints in clinical trials.
    Neuhäuser M
    Fundam Clin Pharmacol; 2006 Dec; 20(6):515-23. PubMed ID: 17109645
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A unifying approach to non-inferiority, equivalence and superiority tests via multiple decision processes.
    Hirotsu C
    Pharm Stat; 2007; 6(3):193-203. PubMed ID: 17879327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison of multiple testing procedures for the gold standard non-inferiority trial.
    Röhmel J; Pigeot I
    J Biopharm Stat; 2010 Sep; 20(5):911-26. PubMed ID: 20721781
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Joint hypothesis testing and gatekeeping procedures for studies with multiple endpoints.
    Mascha EJ; Turan A
    Anesth Analg; 2012 Jun; 114(6):1304-17. PubMed ID: 22556210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Power and sample size when multiple endpoints are considered.
    Senn S; Bretz F
    Pharm Stat; 2007; 6(3):161-70. PubMed ID: 17674404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exact sample-size determination in testing non-inferiority under a simple crossover trial.
    Lui KJ; Chang KC
    Pharm Stat; 2012; 11(2):129-34. PubMed ID: 22232060
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiplicity and flexibility in clinical trials.
    Brannath W; Koenig F; Bauer P
    Pharm Stat; 2007; 6(3):205-16. PubMed ID: 17674349
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An efficient method for accommodating potentially underpowered primary endpoints.
    Li J; Mehrotra DV
    Stat Med; 2008 Nov; 27(26):5377-91. PubMed ID: 18759248
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The assessment of non-inferiority in a gold standard design with censored, exponentially distributed endpoints.
    Mielke M; Munk A; Schacht A
    Stat Med; 2008 Nov; 27(25):5093-110. PubMed ID: 18570271
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiple comparisons to both a negative and a positive control.
    Hasler M
    Pharm Stat; 2012; 11(1):74-81. PubMed ID: 22232049
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TACT method for non-inferiority testing in active controlled trials.
    Wang SJ; Hung HM
    Stat Med; 2003 Jan; 22(2):227-38. PubMed ID: 12520559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A note on the conservativeness of the confidence interval approach for the selection of non-inferiority margin in the two-arm active-control trial.
    Sankoh AJ
    Stat Med; 2008 Aug; 27(19):3732-42. PubMed ID: 18407575
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Testing superiority and non-inferiority hypotheses in active controlled clinical trials.
    Tsong Y; Zhang JJ
    Biom J; 2005 Feb; 47(1):62-74; discussion 99-107. PubMed ID: 16395997
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bayesian design and analysis of composite endpoints in clinical trials with multiple dependent binary outcomes.
    Zaslavsky BG
    Pharm Stat; 2013; 12(4):207-12. PubMed ID: 23625660
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Superiority inferences on individual endpoints following noninferiority testing in clinical trials.
    Logan BR; Tamhane AC
    Biom J; 2008 Oct; 50(5):693-703. PubMed ID: 18932132
    [TBL] [Abstract][Full Text] [Related]  

  • 37. On non-inferiority analysis based on delta-method confidence intervals.
    Rothmann MD; Tsou HH
    J Biopharm Stat; 2003 Aug; 13(3):565-83. PubMed ID: 12921402
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A multiple comparison procedure to control the strong stagewise family error rate in comparing test treatments and a control.
    Chen M; Kianifard F
    J Biopharm Stat; 1997 Jul; 7(3):355-67. PubMed ID: 9252830
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A combined superiority and non-inferiority approach to multiple endpoints in clinical trials.
    Bloch DA; Lai TL; Su Z; Tubert-Bitter P
    Stat Med; 2007 Mar; 26(6):1193-207. PubMed ID: 16791905
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessing departure from dose linearity under a repeated measures incomplete block design.
    Cheng B; Chow SC
    Pharm Stat; 2011; 10(4):357-62. PubMed ID: 21104786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.